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ABSTRACT
Objective: To evaluate the expression of epithelial
membrane protein-2 (EMP2) protein and its
clinicopathological associations in patients with
nasopharyngeal carcinoma.
Design: Retrospective population-based cohort study.
Setting: This study was based on a biobank in Chi-Mei
Medical Center (Tainan, Taiwan) from 1993 to 2002.
Participants: Biopsies of 124 consecutive
nasopharyngeal carcinoma patients without initial
distant metastasis and treated with consistent
guidelines were assessed. Immunoexpressions of
EMP2 were analysed and the outcomes were correlated
with clinicopathological features and patient survivals.
Primary and secondary outcome
measures: Immunoexpressions of EMP2 were
analyzed and the outcomes were correlated with
clinicopathological features and patient survivals.
Results: Loss of EMP2 expression (49.2%) was
correlated with advanced primary tumour (p¼0.044),
nodal status (p¼0.045) and the 7th American Joint
Committee on Cancer stage (p¼0.027). In multivariate
analyses, loss of EMP2 expression emerged as an
independent prognosticator for worse disease-speciﬁc
survival (DSS; p¼0.015) and local recurrence-free
survival (LRFS; p¼0.030), along with the American
Joint Committee on Cancer stages IIIeIV (p¼0.034,
DSS; p¼0.023, LRFS).
Conclusions: Loss of EMP2 expression is common
and associated with adverse prognosticators and
might confer tumour aggressiveness through
hampering its interaction with speciﬁc membrane
protein(s) and hence the downstream signal
transduction pathway(s).
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is an
endemic head and neck epithelial malignancy
in Southeastern Asia and Taiwan, strongly
linked to EpsteineBarr virus (EBV).
1e3 The
latter association is especially authentic for
the differentiated and undifferentiated
non-keratinising carcinoma types, according
to current WHO tumour classiﬁcation,
although genetic and environmental factors
also play certain roles in pathogenesis.
124The
advances in diagnostic imaging, radiation
therapy and adjuvant chemotherapy of NPC
have achieved better locoregional control,
while it appears less satisfactory in ﬁnal treat-
ment outcomes.
56Even though being an
important parameter, Tumour, Node, Metas-
tasis staging still has space to improve in terms
of providing the optimal prognostication to
the patients.
157Therefore, to identify
potential biomarkers with better correlation to
tumour growth and/or treatment outcomes in
patients with NPC, subsequently, to aid in risk
stratiﬁcation and perhaps development of
therapeutic targets, are indispensable.
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ARTICLE SUMMARY
Article focus
- Recent studies have suggested that EMP2 plays
a tumour suppressor role in B cell lymphomas.
- Immunoexpression of EMP2 was retrospectively
assessed in biopsies of 124 consecutive patients
with nasopharyngeal carcinoma.
Key messages
- Loss of EMP2 expression signiﬁcantly correlates
with advanced primary tumour, nodal status and
AJCC stage.
- In multivariate analyses, loss of EMP2 expres-
sion emerges as an independent prognosticator
for worse disease-speciﬁc survival and local
recurrence-free survival.
Strengths and limitations of this study
- Signiﬁcant correlation between loss of EMP2
expression and several clinicopathologic vari-
ables supported its potential role in nasopharyn-
geal carcinomas.
- The molecular mechanisms underlying EMP2
action require to be elucidated.
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Open Access ResearchHuman epithelial membrane protein-2 gene (EMP2),
mapped to chromosome 16, is highly conserved across
vertebrates.
8e10 The expression pattern of EMP2 partially
overlaps to that of the peripheral myelin protein 22
(PMP22, also known as the growth arrest-speciﬁc-3,
GAS3) transcript. By containing the claudin domain and
sharing approximately 40% amino acid identity with
PMP22/GAS3,
11 the EMP2 protein was detected as
a novel member of this four-transmembrane (tetraspan)
superfamily.
12 In humans, EMP2 has a discrete cell type
and tissue distribution, with high levels observed in the
lung and moderate levels in the eye, heart, thyroid,
uterus and intestine.
11 13 14 Functionally, the best
understood tetraspan proteins are connexins, which
form the major structural element of gap junctions.
Connexins play important roles in the regulation of cell
growth and differentiation. Cancer cells usually have
downregulated levels of gap junctions, and several lines
of evidence suggest that loss of gap junctional intercel-
lular communication is an important step in carcino-
genesis. Re-expression of connexins in cancer cells causes
normalisation of cell growth control and reduced tumour
growth.
15 Accordingly, we aimed to systematically analyse
EMP2 immunoexpression in patients with NPC and
identiﬁed that loss of EMP2 expression is associated with
adverse prognosticators, conferring to poor survivals.
MATERIALS AND METHODS
Patients and tumour specimens
The institutional review board approved the study by
using formalin-ﬁxed tissue of NPC for this study
(IRB100-09-003). Available parafﬁn-embedded tissue
blocks were retrieved from 124 NPC patients who
underwent biopsy between January 1993 and December
2002. These patients were free of distant metastasis at
initial presentation. The histological subtypes were
reappraised according to the current WHO classiﬁcation
and, the tumour staging was re-evaluated with the 7th
American Joint Committee on Cancer (AJCC) system by
two pathologists, independently.
Immunohistochemical staining and assessment of EMP2
expression
Tissue sections of 3 mm thickness were cut onto
precoated slides from parafﬁn-embedded tissue blocks
and were next routinely deparafﬁnized with xylene and
rehydrated with ethanol washes. Slides were heated by
the microwave in a 10 mM citrate buffer (pH 6.0) for
7 min to retrieve antigens. Endogenous peroxidase was
blocked with 3% H2O2. Slides were next washed by Tris-
buffered saline for 15 min and subsequently incubated
with a rabbit polyclonal primary antibody targeting
EMP2 (Atlas Antibodies, Stockholm, Sweden) at a dilu-
tion of 1:75 for 1 h. Primary antibodies were detected
using the DAKO ChemMate EnVision Kit (K5001,
Carpinteria, California, USA). The slides were incubated
and developed with the secondary antibody for 30 min
and 3,3-diaminobenzidine for 5 min, followed by coun-
terstained using Gill’s haematoxylin. Immunoexpression
of EMP2 was scored by two pathologists (C-FL and
H-YH) using a multiheaded microscope to reach
a consensus for each case without prior knowledge of
clinical and follow-up information. The percentage of
tumour cells with EMP2 immunoexpression was
recorded for each specimen and loss of EMP2 expres-
sion (negative) was deﬁned in cases with staining #5%
tumour cells (see the Statistical analysis section).
Treatment and follow-up
All 124 patients with follow-up for outcome have
received complete course of radiotherapy (RT, total dose
$7000 cGy) and also cisplatin-based chemotherapy in
those of stage IIeIV diseases, based on the previously
published protocol.
16 The method of RT was in general
uniform within this period. All patients were regularly
monitored after RTuntil death or their last appointment
with the mean follow-up duration being 59.6 months
(range: 4e117).
Statistical analysis
Statistics were performed using SPSS V.14.0 software
(SPSS Inc). c
2 Test was used to compare the EMP2
expression status and various clinicopathological
parameters. The end points analysed were disease-
speciﬁc survival (DSS) and local recurrence-free survival
(LRFS), calculated from the starting date of RT to the
Table 1 Clinical pathological features of 124
nasopharyngeal carcinomas
Variable n (%)
Gender
Male 95 (76.6)
Female 29 (23.4)
Age (years)
<60 98 (79.0)
$60 26 (21.0)
Primary tumour (T)
T1 30 (24.2)
T2 50 (40.3)
T3 21 (16.9)
T4 23 (18.5)
Nodal status (N)
N0 24 (19.4)
N1 32 (25.8)
N2 48 (38.7)
N3 20 (16.1)
Stage
I 7 (5.6)
II 31 (25.0)
III 46 (37.1)
IV 40 (32.2)
Histological grade
Keratinising 5 (4.0)
Non-keratinising/differentiated 54 (43.5)
Non-keratinising/undifferentiated 65 (52.4)
EMP2 expression level
Positive (>5% tumour cells) 63 (50.8)
Negative (#5% tumour cells) 61 (49.2)
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EMP2 low expression in nasopharyngeal carcinomadate of event developed. Patients lost to follow-up were
censored on the latest follow-up date. Survival curves
were plotted using the KaplaneMeier method, and the
log-rank test was performed to evaluate prognostic
differences between groups. Multivariate analysis was
carried out by the Cox proportional hazards model.
However, as a component factor of the AJCC stage,
primary tumour (T) and nodal status (N) was not
introduced in multivariate comparisons. After testing
a series of cut-off values in 5% increment, EMP2
expression was construed as negative when the expres-
sion index was #5% tumour cells. For all analyses, two-
sided tests of signiﬁcance were used with p<0.05
considered signiﬁcant.
RESULTS
Immunohistochemical expression of EMP2 and associations
with clinicopathological variables in NPC specimens
As shown in table 1, 124 cases of NPC consisted of ﬁve
keratinising squamous cell carcinomas, 54 non-kerati-
nising differentiated carcinomas and 65 non-keratinising
undifferentiated carcinomas. A total of 95 men and 29
women with a mean age of 48.6 years (range, 20e83)
were included. Seven cases were classiﬁed as stage I, 31
as stage II, 46 as stage III and 40 as stage IV. Immu-
noexpression of EMP2 was observed and successfully
scored in all cases. Tumour-adjacent normal respiratory
epithelium (ﬁgure 1A) or non-tumour epithelium with
squamous metaplasia (ﬁgure 1B) could be appreciated
in 71 samples and all showed intense EMP2 immu-
noexpression. A wide range of stained tumour cell,
characterised by cytoplasmic and/or membranous
staining, varying from 0% to 90% (median, 30%)
were detected in tumour elements. Of these, 63 cases
showed characteristic EMP2 staining (>5% tumour cells;
ﬁgure 1C), while 61 cases were <5% staining and
therefore classiﬁed as EMP2 negative (ﬁgure 1D). Loss
of EMP2 expression was signiﬁcantly associated with
cases featuring increment of primary tumour (p¼0.004),
nodal status (p¼0.045) and AJCC stage (p¼0.027)
(table 2). However, no signiﬁcant association between
the EMP2 expression level and other clinicopathological
factor was found.
Prognostic impact of EMP2 expression in NPC
Patients with NPC more frequently progressed to
disease-speciﬁc mortality with N2eN3 nodal status
(p¼0.002) and stages IIIeIV (p¼0.007) (table 3).
Besides, patients with advanced AJCC stages IIIeIV held
shorter DSS (p¼0.07; ﬁgure 2A) and LRFS (p¼0.06;
ﬁgure 2B). The development of local recurrence was
signiﬁcantly associated with T3eT4 (p¼0.027), N2eN3
status (p¼0.023) and AJCC stages IIIeIV (p¼0.005) with
a medium duration of 24 months (table 3). Of note,
EMP2 negative correlated to a more aggressive clinical
course with a signiﬁcantly shorter DSS (p¼0.002;
ﬁgure 2C) and LRFS (p¼0.005; ﬁgure 2D) in patients
with NPC. In multivariate analysis (table 4), loss of EMP2
expression steady remained as a robust prognosticator
for both inferior DSS (p¼0.015, HR¼1.969) and worse
LRFS (p¼0.030, HR¼2.136), following tumour stage
(p¼0.034, HR¼2.115; p¼0.023, HR¼3.046, for DSS and
LRFS, respectively).
DISCUSSION
Loss of EMP2 immunostaining as one potent prognos-
ticator for both DSS and LRFS in a subset of patients
with NPC was sustained in this study. Intriguingly, we
Figure 1 Immunohistochemically
non-tumour respiratory epithelium
(A) and those with squamous
metaplasia (B) demonstrate
diffuse and strong EMP2
immunoexpression, which can
also be appreciated in
representative non-keratinising
carcinoma (C) but not in
undifferentiated one (D).
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EMP2 low expression in nasopharyngeal carcinomahave also identiﬁed a signiﬁcant association between loss
of EMP2 expression and the overexpression of latent
membrane protein 1 (p¼0.007, data not shown), an
important oncoprotein of EBV,
17 suggesting a potential
role of EMP2 loss in EBV-associated tumour progression.
However, signiﬁcantly high EMP2 expression was found
in ovarian cancer through activation of caveolins/glyco-
sylphosphatidyl inositol-linked proteins
18 and was iden-
tiﬁed as an early predictor of endometrial cancers with
unfavourable outcome.
19 Due to non-neoplastic
Table 2 Expression level of EMP2 and correlations with clinicopathologic variables (n¼124)
Variable
EMP2 expression score
p Value
Positive (>5%
tumour cells)
Negative (£5%
tumour cells)
Gender 0.926
Male 43 52
Female 20 9
Age (years) 0.926
<60 50 48
$60 13 13
Primary tumour (T) 0.044*
T1eT2 46 34
T3eT4 17 27
Nodal status (N) 0.045*
N0eN1 34 22
N2eN3 29 39
Stage 0.027*
IeII 25 13
IIIeIV 38 48
Histological grade 0.879
Keratinising 3 2
Non-keratinising/differentiated 28 26
Non-keratinising/undifferentiated 32 33
*Statistically signiﬁcant.
Table 3 Univariate log-rank analysis of EMP2 expression score on survival outcome (n¼124)
Variable n
DSS LRFS
n p Value n p Value
Gender 0.878 0.346
Male 95 45 30
Female 29 14 7
Age (years) 0.996 0.755
<60 98 48 29
$60 26 11 8
Primary tumour (T) 0.065 0.027*
T1eT2 80 32 19
T3eT4 44 27 18
Nodal status (N) 0.002* 0.023*
N0eN1 56 18 12
N2eN3 68 41 25
Stage 0.007* 0.005*
IeII 38 10 3
IIIeIV 86 49 32
Histological grade 0.157 0.900
Keratinising/non-keratinising 47 40 15
Undifferentiated 77 39 22
EMP2 expression level 0.002* 0.005*
Positive (>5% tumour cells) 63 21 13
Negative (#5% tumour cells) 61 38 24
*Statistically signiﬁcant.
DSS, disease-speciﬁc survival; LRFS, local recurrence-free survival.
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EMP2 low expression in nasopharyngeal carcinomaperitoneal, surface tissues were complete negative for
EMP2 staining, thus EMP2 was regarded as increased
expression in tumour cells in ovarian cancer.
20 Moder-
ately intense diffuse immunohistochemical stainings of
tumour cell cytoplasm were identiﬁed in endometrioid
adenocarcinoma, serous carcinoma, mixed endome-
trioid and serous carcinoma, mixed endometrioid and
clear cell carcinoma.
21 On the other hand, compared
with undifferentiated ones, predominant expressions of
EMP2 in cytoplasm and/or membrane of squamous
metaplasias and non-keratinising NPCs were found in
our study, suggesting that loss of EMP2 expression might
change its interactions with some membrane proteins in
NPC. Surface expression of the a6b1 integrin was
speciﬁcally increased by EMP2 in NIH3T3 ﬁbroblasts.
22
Moreover, surface expression and trafﬁcking of integrin
Figure 2 KaplaneMeier plotting
illustrates the prognostic
signiﬁcance of tumour stage for
(A) disease-speciﬁc survival
(DSS) and (B) local recurrence-
free survival (LRFS), respectively.
The predictive value of EMP2
expression is also demonstrated
(C, D).
Table 4 Multivariate survival analysis of EMP2 expression level on survival outcome
Variable
DSS LRFS
HR (95% CI) p Value HR (95% CI) p Value
AJCC stage 0.034* 0.023*
IeII 1 1
IIIeIV 2.115 (1.057 to 4.232) 3.046 (1.171 to 7.919)
EMP2 expression level 0.015* 0.030*
Positive (>5% tumour cells) 1 1
Negative (#5% tumour cells) 1.969 (1.144 to 3.391) 2.136 (1.076 to 4.237)
*Statistically signiﬁcant.
AJCC, American Joint Committee on Cancer; DSS, disease-speciﬁc survival; LRFS, local recurrence-free survival.
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EMP2 low expression in nasopharyngeal carcinomaavb3 during the window of implantation, which are
essential for endometrialeblastocyst interaction in mice,
were affected by the EMP2 level and the association
between EMP2 and focal adhesion kinase.
19 23 24 In
mammals, 18 a and eight b subunits assemble into 24
different integrins, which bind collagens, laminins or
arginineeglycineeaspartic acid-containing proteins.
Integrins are regulated by conformational changes,
clustering and trafﬁcking, and regulatory mechanisms
differ strongly between individual integrins and between
cell types. Defective integrin activation or integrin
signalling is associated with an array of pathological
conditions.
25 Endocytosis and recycling are crucial in the
regulation of integrin turnover and redistribution in
adherent cells, especially during dynamic processes such
as migration and invasion.
26 Therefore, EMP2 probably
plays a tumour suppressor role through interacting with
speciﬁc integrin(s) in epithelial cells and, thereafter,
manages regular signalling transduction in benign
conditions.
In addition to the above ﬁnding, we uncovered that
ectopic expression of EMP2 in a malignant human
urothelial cell line, J82, signiﬁcantly reduced cell
proliferation, cell cycle progression, migration and
invasion in vitro (unpublished). Consistently, suppres-
sion subtractive hybridisation technologies isolated
mouse orthologue Emp2, which suppresses B cell
lymphoma tumorigenicity through a functional tumour
suppressor phenotype.
10
The susceptibility to allogeneic cytotoxic T lympho-
cytes of a mouse malignant, Emp2-deﬁcient cell line
(MV)
10 has been enhanced by retroviral overexpression
of Emp2 gene.
27 Constitutive overexpression of EMP2 or
other epithelial membrane proteins including EMP1,
EMP3 and PMP22, in human HEK293 epithelial cells,
leading to the development of apoptotic phenotypes,
were demonstrated by purinergic receptor P2X, ligand-
gated ion channel, 7 (P2RX7)-mediated cell blebbing,
annexin V binding to plasma membrane and cell death,
through a caspase-dependent pathway. Physically, the
C-terminal domain of P2RX7 protein associates with
EMPs and mediates some aspects of the downstream
signalling following P2RX7 activation.
28 All these studies
supported our clinical observations, reinforcing that
EMP2 might play distinct characteristics in different
cellular contexts. Indeed, the aetiology of NPC is
complex, including a host of viral, genetic and environ-
mental factors.
32 93 0In spite of cure for the majority of
the patients, challenges still exist in the prevention of
disease relapse and treatment of patients with refractory
or metastatic NPC.
31e33 Therefore, for the ﬁrst time, loss
of EMP2 expression was identiﬁed as a biomarker inde-
pendently correlated with tumour aggression to facilitate
appropriate allocation of adjuvant therapy, suggesting
its signiﬁcance for patient-tailored strategy to manage
high-risk NPCs.
Except for loss of EMP2 expression, signiﬁcantly
increased HRs of DSS and LRFS in NPC patients with
higher stages (IIIeIV) were further ascertained, analo-
gous to other studies.
34e36 Additionally, we revealed
signiﬁcant correlations between loss of EMP2 expression
and primary tumour, nodal status and stage in NPCs,
indicating its prospective role in preventing NPC
progression and aggressiveness. Although the precise
characteristics of the EMP2 protein in NPC progression
remain to be elucidated, the potential utility of EMP2
immunostaining as a prognostic biomarker in NPCs is
assured.
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